Blegdamsvej 3, 2200 København N, Building: 07-11-85
The VLP group (VAR2CSA team) is using a virus-like-particle (VLP) based platform to adjuvant antigens for vaccine purposes. I am involved in vaccine production, formulation, quality assessment and immunization as well as development and optimization of our adjuvanting VLP system.
During my education I have been involved in preclinical studies with different VLP platforms designed to adjuvant low immunogenic antigens especially related to malaria. As a postdoc, I have been involved in using the VLP platform as an immunotherapeutic treatment for HER2 related breast cancer in mice. Several techniques are involved in this process such as; cloning and purification of proteins and VLPs, electron microscopy and dynamic light scattering for quality assessment as well as immunoassays to assess the response to the vaccine.